Tenaya Therapeutics (TNYA) AI Stock Analysis

• Market Cap: $156.76M
• Dividend Yield: N/A
• Average Volume (3M): 4.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: N/A
• EPS Growth: 46.68%
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 216,998,870
• 10 Day Avg. Volume: 2,873,734
• 30 Day Avg. Volume: 4,003,933
• PEG Ratio: 0.02
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.58
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.37
• 1Y Price Target: $4.20
• Price Target Upside: 215.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.46
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $0.72 ▼(-45.71% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held down primarily by weak financial performance (no revenue, large losses, and sustained cash burn despite some improvement), partially offset by improving near-term technical momentum. Corporate events are mixed, with the Alnylam collaboration supportive but tempered by Nasdaq deficiency risk, while valuation is limited by negative earnings and no indicated dividend.

Positive Factors

Strategic collaboration with Alnylam

A large, structured collaboration transfers downstream development and commercialization cost to Alnylam while providing upfront payments and milestone upside. This materially reduces Tenaya's capital required to advance targets and validates its discovery platform, improving long-term de‑risking and funding optionality.

Negative Factors

No product revenue; persistent net losses

Zero revenue and recurrent large losses mean the company cannot self-fund development and is reliant on external capital or partners. Over several quarters this raises dilution risk, limits reinvestment capacity, and keeps long-term sustainability contingent on clinical or partnering success.

Tenaya Therapeutics Business Overview & Revenue Model

Company Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The com...

Read more

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The com...

How the Company Makes Money

Tenaya Therapeutics primarily generates revenue from collaboration and partnership arrangements rather than product sales, as it is a clinical-stage company and does not have approved commercial products. Its revenue model is typically driven by p...

Read more

Tenaya Therapeutics primarily generates revenue from collaboration and partnership arrangements rather than product sales, as it is a clinical-stage company and does not have approved commercial products. Its revenue model is typically driven by p...

Tenaya Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-8.44M	-8.47M	-8.69M	-8.71M	-4.03M
EBITDA	-84.89M	-102.66M	-115.40M	-114.95M	-68.70M
Net Income	-90.60M	-111.13M	-124.08M	-123.67M	-72.72M
Balance Sheet
Total Assets	146.92M	119.94M	170.51M	278.94M	316.65M
Cash, Cash Equivalents and Short-Term Investments	100.55M	61.45M	104.64M	186.53M	251.30M
Total Debt	10.83M	13.61M	12.42M	15.10M	15.70M
Total Liabilities	23.66M	27.09M	31.09M	35.57M	38.12M
Stockholders Equity	123.27M	92.85M	139.42M	243.38M	278.53M
Cash Flow
Free Cash Flow	-68.88M	-91.53M	-103.31M	-125.05M	-85.93M
Operating Cash Flow	-68.26M	-90.50M	-102.07M	-104.42M	-60.81M
Investing Cash Flow	56.08M	1.13M	48.72M	83.65M	-238.56M
Financing Cash Flow	108.41M	47.75M	4.05M	77.77M	208.97M

Tenaya Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNYA, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.74, and above the 200-day MA of 1.02, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 10.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNYA.

Tenaya Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECX	54 Neutral	$583.20M	-5.15	-26.87%	―	―	60.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNYA	50 Neutral	$156.76M	-1.20	-85.20%	―	―	46.68%
ABEO	47 Neutral	$252.16M	3.92	53.18%	―	―	―
VYGR	47 Neutral	$240.19M	-1.93	-48.94%	―	-80.88%	-388.61%
CADL	47 Neutral	$365.50M	―	-51.44%	―	―	68.53%
GALT	46 Neutral	$188.92M	-8.32	32.59%	―	―	18.82%

Tenaya Therapeutics Corporate Events